Fig. 4.

Varying IC score (%) in triple-negative breast cancer. For assessment, PD-L1 IHC was used (PD-L1 clone SP263). A The first case did not show any PD-L1 positivity and was therefore considered PD-L1-negative (IC score = 0%). ×100. B, C Both samples display an IC score >1% with C showing many more positive tumor-associated immune cells (IC score = 25%) than B (IC score = 4.5%). D The IC score is >1%; however, note the strongly membranously PD-L1-positive tumor cells which are clearly larger than the mostly granular stained immune cells; the tumor cells must not be considered for the IC score (IC score = 5%). B–D ×200.